Publications
5674 Results
- Journal / Conference
- Society for Clinical Trials 2010 Meeting; poster
- Year
- 2010
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S0000
Video productions in SELECT: effective tools for staff learning and participant motivation in clinical trials
- Journal / Conference
- Journal of Clinical Oncology 28:7s (suppl; abstr 8517) ASCO 2010 Meeting; poster
- Year
- 2010
- Research Committee(s)
- Melanoma
- Study Number(s)
- S0008
Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from the SWOG S0008 phase III randomized adjuvant trial
- Journal / Conference
- Journal of Clinical Oncology 28:7s (suppl; abstr 8513); ASCO 2010 Meeting; poster
- Year
- 2010
- Research Committee(s)
- Melanoma
- Study Number(s)
- S0008
Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes is an independent prognostic factor for survival in stage III melanoma (mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008
- Journal / Conference
- Journal of Clinical Oncology 28:7s (suppl; abstr 4569); ASCO 2010 Meeting; poster
- Year
- 2010
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0028
Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced (adv) urothelial cancer (UC), aged > 70 years 9yrs): SWOG 0028
- Journal / Conference
- Journal of Clinical Oncology 28:7s (suppl; abstr 5555); ASCO 2010 Meeting; poster
- Year
- 2010
- Research Committee(s)
- Head and Neck
- Study Number(s)
- S0329
A phase II trial of biweekly gemcitabine and paclitaxel (GEMTAX) with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study
- Journal / Conference
- Journal of Clinical Oncology 28:7s, 2010 (suppl;abstr TPS342); ASCO; poster
- Year
- 2010
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0421
Circulating tumor cell capture and analysis in a multi-center SWOG-coordinated prostate cancer trial
- Journal / Conference
- Journal of Clinical Oncology 28:7s (suppl; abstr 8502); ASCO 2010 Meeting; oral
- Year
- 2010
- Research Committee(s)
- Melanoma
- Study Number(s)
- S0438
Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group trial S0438
- Journal / Conference
- Journal of Clinical Oncology 28:7s (suppl; abstr TPS223); poster
- Year
- 2010
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S0727
A randomized phase II trial of combination gemcitabine + erlotinib + IMC-A12 (cixutumumab) vs. gemcitabine + erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer: Southwest Oncology Group Study (SWOG S0727)
- Journal / Conference
- Journal of Clinical Oncology 28:72s(suppl; abstr 511); oral
- Year
- 2010
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-8814
Potential tumor biologic causes of the racial survival disparity in ER-positive breast cancer adjuvant trials
- Journal / Conference
- American Urological Association Annual Meeting; late breaking, oral
- Year
- 2010
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S9917